Strides Pharma Science Limited — Updates, 18-05-2026: General Updates

Strides Pharma reported robust FY26 financials: Revenue at ₹4,858.7 Cr (+6.4%), EBITDA at ₹925.3 Cr (+15.3%), and Operational PAT at ₹518.1 Cr (+50.3%). Strong Ex-US market growth of 21% YoY fueled performance. Board declared a ₹5/share dividend.